Q1 EPS Estimates for Vera Therapeutics Increased by Wedbush

Vera Therapeutics, Inc. (NASDAQ:VERA) – Stock analysts at Wedbush lifted their Q1 2025 EPS estimates for Vera Therapeutics in a research note issued to investors on Thursday, February 27th. Wedbush analyst L. Chico now forecasts that the company will earn ($0.72) per share for the quarter, up from their previous forecast of ($0.81). Wedbush has a “Neutral” rating and a $38.00 price target on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. Wedbush also issued estimates for Vera Therapeutics’ Q2 2025 earnings at ($0.73) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.20) EPS, FY2026 earnings at ($3.58) EPS, FY2027 earnings at ($2.08) EPS and FY2028 earnings at $0.20 EPS.

VERA has been the subject of a number of other reports. Wells Fargo & Company initiated coverage on Vera Therapeutics in a report on Thursday, November 21st. They issued an “overweight” rating and a $70.00 price target for the company. JPMorgan Chase & Co. boosted their target price on shares of Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Guggenheim raised their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. The Goldman Sachs Group assumed coverage on shares of Vera Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $58.00 price objective for the company. Finally, Wolfe Research began coverage on shares of Vera Therapeutics in a research note on Tuesday, February 4th. They set an “outperform” rating and a $49.00 price objective on the stock. One analyst has rated the stock with a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $65.11.

Vera Therapeutics Trading Down 5.1 %

Shares of NASDAQ VERA opened at $28.41 on Monday. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The stock’s 50 day moving average price is $35.47 and its two-hundred day moving average price is $40.28. Vera Therapeutics has a 52-week low of $25.99 and a 52-week high of $51.61. The stock has a market capitalization of $1.80 billion, a P/E ratio of -10.89 and a beta of 1.11.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.11.

Insider Buying and Selling at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 17,500 shares of the stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $43.07, for a total value of $753,725.00. Following the completion of the transaction, the chief executive officer now directly owns 85,942 shares of the company’s stock, valued at $3,701,521.94. This represents a 16.92 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last 90 days, insiders have sold 52,500 shares of company stock worth $2,305,625. 21.70% of the stock is owned by company insiders.

Institutional Trading of Vera Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Huntington National Bank bought a new position in shares of Vera Therapeutics in the fourth quarter worth $26,000. AlphaQuest LLC acquired a new stake in Vera Therapeutics in the fourth quarter worth about $34,000. GF Fund Management CO. LTD. bought a new position in Vera Therapeutics in the 4th quarter valued at about $56,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Vera Therapeutics by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock valued at $86,000 after buying an additional 350 shares during the period. Finally, KBC Group NV raised its position in shares of Vera Therapeutics by 127.2% during the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock worth $105,000 after buying an additional 1,387 shares in the last quarter. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.